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ABSTRACT
Integrative Analysis to Evaluate Similarity Between
BRCAness Tumors and BRCA Tumors
Weston Reed Bodily
Department of Biology, BYU
Master of Science
The term “BRCAness” is used to describe breast-cancer patients who lack a germline
mutation in BRCA1 or BRCA2, yet who are believed to express characteristics similar to
patients who do have a germline mutation in BRCA1 or BRCA2. Although it is hypothesized
that BRCAness is related to deficiency in the homologous recombination repair (HRR)
pathways, relatively little is understood about what drives BRCAness or what criteria should be
used to assign patients to this category. We hypothesized that patients whose tumor carries a
genomic or epigenomic aberration in BRCA1 or BRCA2 should be classified under the
BRCAness category and that these tumors would exhibit downstream effects (additional
mutations or gene-expression changes) similar to patients with germline BRCA1/2 mutations. To
better understand BRCAness, we examined similarities and differences in gene-expression
profiles and somatic-mutation "signatures" among 1054 breast-cancer patients from The Cancer
Genome Atlas. First, we categorized patients into three categories: those who carried a germline
BRCA1/2 mutation, those whose tumor carried a genomic aberration or DNA hypermethylation
in BRCA1/2 (the BRCAness group), and those who fell into neither of the first two groups. Upon
evaluating the gene-expression data in context of the PAM50 subtypes, we did not observe
significant similarity between the germline BRCA1/2 and BRCAness groups, but we did observe
enrichment within the basal subtype, especially for BRCAness tumors with hypermethylation of
BRCA1/2. However, the gene-expression profiles were fairly heterogeneous; for example,
BRCA1 patients differed significantly from BRCA2 patients. In agreement with prior findings,
certain mutational signatures—especially "Signature 3"—were enriched for patients with
germline BRCA1/2 mutations as well as for BRCAness patients. Furthermore, we observed
significant similarity between germline BRCA1/2 patients and patients with germline mutations
in PALB2, RAD51B, and RAD51C, genes that are key parts of the HRR pathway and that
interact with BRCA1/2. Our findings suggest that the BRCAness category does have biological
and clinical relevance but that the criteria for including patients in this category should be
carefully defined, potentially including BRCA1/2 hypermethylation and homozygous deletions
as well as germline mutations in PALB2, RAD51B, and RAD51C.
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INTRODUCTION
Approximately 1-5% of breast cancer patients have a germline mutation in either the
BRCA1 or BRCA2 gene. These individuals have a 30-70% chance of developing breast cancer
in their lifetime. BRCA1 and BRCA2 play important roles in DNA repair, specifically
homologous recombination repair (HRR) of double-stranded breaks. When double-stranded
breaks have occurred, cells to develop into cancerous tumors rather than enter apoptosis.
Many patients exhibit clinical responses that are characteristic of those who carry
germline BRCA1/2 mutations, even though they lack germline BRCA1/2 mutations. This
phenomenon, known as "BRCAness", may result from genomic or epigenomic aberrations that
have similar, downstream biological effects as germline mutations in BRCA1/2. Such
downstream effects may include an increase in double-stranded breaks and other HRR
deficiencies, but relatively little is understood about the biological drivers and effects of
BRCAness. As a result, relatively little is understood about what specific criteria should be used
to assign patients to this category. If reliable BRCAness criteria could be identified, better or
more specific treatments for BRCAness patients could be applied. For example, treatments for
BRCA1/2 patients commonly include PARP inhibitors and platinum-salt therapies, which target
cells with HRR defects. Because there is a possible link between BRCAness and HRR
deficiencies, it is possible that these same treatments could be effective for BRCAness patients
as well.Various criteria have been proposed to classify patients into the BRCAness category;
these criteria include somatic mutations in BRCA1/2, large scale (chromosomal) deletions in
HRR genes, tumor-mutational signatures, hypermethylation of BRCA1/2 genes, transcriptional
profiles, and germline mutations in HRR genes other than BRCA1 and BRCA2.
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For this study, we used a multi-omic approach to further investigate the BRCAness
phenomenon and to evaluate criteria used to classify patients into this category. We obtained
genomic, epigenomic, and transcriptomic data from The Cancer Genome Atlas (TCGA) for 1054
breast-cancer patients. We hypothesized that breast tumors of patients who meet certain
BRCAness criteria would exhibit tumor gene-expression patterns or mutational-signature
patterns more similar to patients who carry germline mutations in BRCA1 or BRCA2 than to
randomly selected breast cancer patients who do not meet these criteria. Such gene-expression
patterns or mutational signatures would suggest that breast-tumor biology is affected similarly by
germline BRCA1/2 mutations and these other mechanisms and thus that it may be advisable to
treat both groups similarly. By including gene-expression data and mutational-signature data in
our analysis, we were able to examine multiple sources of evidence for downstream effects of
BRCA1/2 mutations simultaneously. For both data types, we found that there was a statistically
significant similarity between patients with germline BRCA1/2 mutations and patients
categorized as BRCAness; we did not observe such similarity between BRCAness patients and
our control group. Upon examining the criteria we used to classify the patients into the
BRCAness category, we observed that similarities in gene expression depended strongly on the
categorization criteria being used. DNA hypermethylation status correlated strongly with
germline-mutation status; however, the same was not true for CNVs or somatic mutations in
BRCA1/2. In addition, we found that tumor-expression patterns from germline BRCA1 patients
differed significantly from tumors from patients who carried a germline BRCA2 mutation. In
contrast, similarity among these groups was quite consistent when examining mutationalsignature profiles. Lastly, we examined germline data for 60 additional breast-cancer
predisposition genes and observed high similarity in the mutational-signature data between
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tumors from BRCA1/2 carriers and tumors from individuals who carried germline mutations in
PALB2, RAD51B, and RAD51C, but not in other genes that play an important role in DNA
repair. Our findings suggest that the BRCAness category does have biological and clinical
relevance but that care must be taken in deciding which patients to classify under this category.

3

Data preparation

METHODS

We obtained breast-cancer patient data from TCGA. For each patient, we obtained data
on germline mutations, somatic mutations, gene methylation, copy-number variations, and geneexpression levels. Firstly, we used these data to categorize each patient into one of the following
categories: BRCA, BRCAness, or Other. Secondly, to determine which criteria could be
beneficial in characterizing BRCAness, we used the data to analyze similarities and differences
among these groups. Due to the heterogeneous nature of how TCGA data are formatted, it was
necessary to reformat the data. Therefore, we wrote computer scripts in the Python programming
language (http://python.org) and restructured the data into the "tidy data" format. The BRCA
group included patients who possessed a germline BRCA1/2 mutation that we deemed to be
pathogenic (or likely pathogenic); the BRCAness group included patients who lacked a known,
pathogenic, germline BRCA1/2 mutation but whose tumor had a somatic mutation (singlenucleotide variant or small insertion/deletion) in BRCA1/2, a homozygous deletion in BRCA1/2,
or hypermethylation in BRCA1/2; the Other group consisted of patients who were identified as
having none of these aberrations.
To determine germline-mutation status, we downloaded raw sequencing data from
CGHub for matching normal (blood) samples in TCGA. We limited our analysis to whole-exome
sequencing samples that had been sequenced using Illumina Genome Analyzer or HiSeq
equipment. Because the sequencing data files were stored in BAM format, we used Picard Tools
(SamToFastq module, version 1.131) to convert them to FASTQ format. We used the BurrowsWheeler Alignment (BWA, version 0.7.12) tool to align the sequencing reads to version 19 of
the GENCODE reference genome (hg19 compatible). We used sambamba (version 0.5.4) to sort,
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index, mark duplicates, and flag statistics for the aligned BAM files. In cases where there were
multiple BAM files per sample, we used bamUtil (1.0.13) to merge the BAM files. When
searching for relevant germline variants, we focused solely on 62 genes that had been included in
the BROCA Cancer Risk Panel (http://tests.labmed.washington.edu/BROCA). We extracted data
for these genes using bedtools (intersectBed module, version 2).
We used Picard Tools (CalculateHsMetrics module) to calculate alignment metrics. For
exome-capture regions across all samples, the average sequencing coverage of target regions was
44.4. The average percentage of target bases that achieved at least 30X coverage was 33.7%. The
average percentage of target bases that achieved at least 100X coverage was 12.3%.
To call DNA variants, we used freebayes (version v0.9.21-18-gc15a283) and Pindel
(https://github.com/genome/pindel). We used freebayes to identify single-nucleotide variants and
small insertions or deletions. We used Pindel to identify larger variants, including deletions and
medium-sized insertions. Having called these variants, we used snpEff (version 4.1) to annotate
the variants and GEMINI (version 0.16.3) to query the variant data. The scripts and code that
were used to process the data can be found in this open-access repository:
https://bitbucket.org/srp33/tcga_germline/overview. We collaborated with Drs. Mary-Claire
King and Brian Shirts from the University of Washington to further filter the germline variants
for pathogenicity.
We classified pathogenic, somatic mutations in each patient by examining preprocessed
data available from the Genomic Data Commons and using the following exclusion criteria: 1)
synonymous variants and variants that snpEff classified as having a “LOW” or “MODIFIER”
effect on protein sequence, 2) variants that SIFT and Polyphen2 both indicated to be benign, and
3) variants that were observed at greater than 1% frequency across all populations in ExAC
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Lastly, we collaborated with our colleagues at the University of Washington to evaluate
pathogenicity of the somatic variants in BRCA1/2 and compared these findings against data
available in the ClinVar database.
We downloaded DNA methylation data via Synapse
(https://www.synapse.org/#!Synapse:syn2320010). These data were generated using the Illumina
HumanMethylation450 platform. To map the methylation probes to genes, we used an annotation
file (Closest_TSS_gene_name column) developed by Price, et al. This file can be accessed from
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL16304. In cases where there were
multiple values per gene, we used the median value. We classified tumor samples as exhibiting
hypermethylation in BRCA1/2 using the getOutliersI function in the extremevalues R package
(version 2.3.2). When invoking this function, we specified the following non-default parameter
values:rho=(1, 1) and FLim=(0.1, 0.9).
We obtained copy-number-variation data from the Xena database
(https://xenabrowser.net/datapages/?dataset=TCGA.BRCA.sampleMap/Gistic2_CopyNumber_G
istic2_all_thresholded.by_genes&host=https://tcga.xenahubs.net). These data were generated
using Affymetrix SNP 6.0 arrays, and CNV calls were made using the GISTIC2 method. The
data had been summarized to gene-level values, and CNV values were summarized using
integer-based discretization. We focused on tumors with a gene count of “-2” for BRCA1 or
BRCA2, which indicated a homozygous deletion in those genes.
We used RNA-Sequencing data that had been preprocessed using the Rsubread package
and summarized to gene-level values. To facilitate biological and clinical interpretation, we
limited the gene-expression data to the The Prosigna™ Breast Cancer Prognostic Gene Signature
(PAM50) genes.
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We derived a mutational-signature profile for each patient using the deconstructSigs
(version 1.8.0) R package using the mutational data for each breast-cancer patient. As input to
this step, we used somatic-mutation data that had not been filtered for pathogenicity, as a way to
ensure adequate representation of each signature. This provided us with a data set that has a
value for each of the mutational signatures for each patient, indicating the “weight” of each
signature. We formatted mutational data using the mut.to.sigs.input function, then used the
whichSignatures function with the included signatures.nature2013 data as the signature profile
data set to process the data.
Analytical Pipeline
We analyzed the PAM50 gene-expression profiles and mutational-signature profiles for
each patient using Rtsne (version 0.11), an R package that implements the t-distributed
Stochastic Neighbor Embedding (t-SNE) algorithm. This algorithm enabled us to further reduce
the dimensionality of the data and visualize similarities and differences among tumors based on
these gene-expression or mutational-signature patterns.
For a given group or groups of patients, we used Cartesian coordinates produced by the tSNE algorithm to determine similarity by calculating the pairwise Euclidean distance between
each patient in the group(s). We then calculated the median of the pairwise Euclidean distances.
To determine whether the similarity within or between groups was statistically significant, we
performed a permutation analysis. First, we created an empirical null distribution against which
we could compare the actual median distances; to create this distribution, we calculated the
median, pairwise Euclidean distance among or between individuals of group(s) the same size
after randomizing the “identity” of each sample. We calculated empirical p-values by finding the
percentage of randomized medians higher than the actual median.
7

RESULTS
The purpose of this study was to evaluate similarity between breast-cancer patients with
germline BRCA1/2 mutations and BRCAness patients. To do this, we categorized patients into
one of three categories (BRCA, BRCAness, Other), and performed an integrative analysis to
evaluate gene-expression profiles and mutational-signature profiles of each patient. Figure 1
illustrates patient counts for each of the patient categories. The Other group contained the largest
number of patients (n = 927), whereas the BRCA group was the smallest, containing only 47
patients.

Figure 1 - Distribution of patients in each patient category.
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As a way to characterize downstream biological effects that may result from genomic
aberrations in BRCA1 or BRCA2, we evaluated gene-expression data from 1054 breast tumors
in TCGA. A profile for each patient consisted of expression values for the 50 genes from the
PAM50 panel (see Methods), which has been demonstrated to have biological and clinical
relevance. We also evaluated mutational signatures for the same cohort of patients (see
Methods). These signatures reflect somatic-mutation patterns of single nucleotide variants in a
trinucleotide context that likely result from lack of DNA damage repair and other aberrant
cellular processes and have been shown to have clinical relevance. This resulted in a data table
containing a weight for each signature for each patient. An example of this output is shown in
Table 1.
Table 1 - Example output of deconstructSigs.

TCGA ID

Signature.1A Signature.1B

Signature.2

Signature.3

...

1

TCGA-B7-XYZ1

0.552

0.000

0.239

0.000

...

2

TCGA-A2-XYZ2

0.000

0.000

1.000

0.000

...

3

TCGA-C3-XYZ3

0.000

0.000

0.000

0.000

...

4

TCGA-D7-XYZ4

0.446

0.000

0.000

0.000

...

5

...

...

...

...

...

...

To reduce the dimensionality of the data, we applied the t-distributed Stochastic
Neighbor Embedding (t-SNE) algorithm to the gene-expression and mutational-signature profile
data. This algorithm produced X and Y coordinates for each patient, which we then plotted
(Figures 2 and 3). These scatterplots illustrate interesting patterns that arise from the data. For
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the mutational-signature data (Figure 2), samples with germline BRCA1 and BRCA2 mutations
cluster primarily in one area that is predominantly populated by “Signature 3” tumors.

Figure 2 - Scatterplot showing the mutational signature profiles.

The t-SNE plot for the gene-expression data (Figure 3) shows a cluster (upper right) that
is distinct from the remaining patients and is populated almost exclusively by tumors of the
"Basal" subtype (PAM50 classification). Nearly all of the patients with BRCA1 germline
mutations fell in this cluster, whereas only four BRCA2 patients fell in this cluster.
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Figure 3 - Scatterplot showing the gene expression profiles.
As a complement to visualizing the data using the t-SNE algorithm, we used a
permutation analysis to evaluate the similarity within and between various groups of patients.
First, we analyzed the homogeneity among BRCA1 patients when compared to themselves,
expecting that there would be a high degree of similarity. The results of this analysis shows
significant similarity (P-value < 0.001) within the BRCA1 group, which is expected (Figure 4).
However, we do not observe statistically significant similarity within the BRCA2 group in the
gene expression context (P-value 0.121). We observe significant similarity within both the
BRCA1 group (P-value <0.001) and the BRCA2 (P-value <0.001) group in the mutational
signature data (Figure 4).
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BRCA1

BRCA2

Gene expression

Mutational
signature

Figure 4 - Permutation analysis comparing BRCA1/2 patients to others with the same mutation
across two data sets.
Next we compared patients in the BRCA category to those in the BRCAness category. As
shown in Figure 5, there was a statistically significant similarity between the BRCA and
BRCAness groups in the mutational signature data (P-value <0.001). However, when this
analysis was repeated with the gene expression data, we found that there isn’t significant
similarity between the two groups.
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Gene expression

Mutational signature

BRCA vs
BRCAness

BRCA vs
Other

Figure 5 - Results of the permutation analysis of BRCA patients compared to BRCAness
patients in two data sets.

A more detailed analysis of the mutational-signature data revealed that all subgroups
within the BRCAness category—hypermethylation, deletions, or somatic mutations—showed
high similarity to patients in the BRCA category, irrespective of whether these aberrations
affected BRCA1 or BRCA2 (Table 2)
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Table 2 - Empirical p-values for subgroup comparisons using the mutational-signature data.

Gene

Deletion

Methylation

Somatic mutation

BRCA 1

<0.001

<0.001

<0.001

BRCA 2

<0.001

0.004

<0.001

BRCA 1&2

<0.001

<0.001

<0.001

A subgroup analysis of the gene-expression data revealed that patients with germline
BRCA1 mutations were highly similar to patients with somatic hypermethylation in BRCA1
(Table 3). However, expression patterns for patients with germline BRCA1 mutations were
significantly different from patients with somatic BRCA1 mutations. Patients with germline
BRCA2 mutations showed similar results. Although only one tumor exhibited hypermethylation
in BRCA2, expression patterns for this tumor were significantly similar to patients with somatic
BRCA2 hypermethylation. Patients with somatic BRCA2 mutations were significantly dissimilar
to patients with patients with germline mutations in this gene.
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Table 3 - Empirical p-values for subgroup comparisons using the gene expression data.

Gene

Deletion

Methylation

Somatic mutation

BRCA 1

0.698

<0.001

0.919

BRCA 2

0.921

0.004

0.983

BRCA 1&2

0.821

0.045

0.007

When we considered BRCA1 and BRCA2 separately for the gene-expression, we
observed a significant difference between patients with either a BRCA1 germline mutation or
tumor hypermethylation and patients with either a BRCA2 germline mutation or somatic
hypermethylation (Table 3). However, when we did the same for the mutation signatures, these
two subgroups were statistically indistinguishable (Table 2).
In our initial evaluations, we only considered somatic aberrations as candidates for
classifying patients into the BRCAness category. However, germline mutations in many other
genes are known to be breast-cancer predisposition genes and may confer similar downstream
effects on tumor biology as BRCA1 or BRCA2. In particular, we were interested in genes that
aid in homologous recombination repair. We searched for germline variants in 60 such genes
(see Methods). Germline variants occurred most frequently in CHEK2 (n=25) and ATM (n=10)
with a long tail of mutations occurring in a variety of other genes (Figure 6).
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Figure 6 - Distribution of germline mutations across several genes.

We used the gene-expression data and mutational signatures to evaluate these genes as
candidates to be included in the BRCAness category. For the gene-expression data, two patients
who carried germline mutations in either RAD51B or RAD51C had a tumor of the Basal
subtype; however, two additional patients with a mutation in RAD51B did not cluster with these
patients. The patterns for the mutational-signature data were more clear. Seven of eight patients
who carried a germline mutation in PALB2, BARD1, RAD51B, or RAD51C clustered tightly
with the Signature 3 samples, even though Signature 3 was the most prominent signature for only
one of these patients. Each of these genes codes for a protein that plays a role in homologous
recombination repair and interacts—whether directly or indirectly—with BRCA1 and/or
BRCA2. Accordingly, we created a new category called HRR+ that consisted of patients who
had a germline mutation in one of these genes. We then used a permutation analysis to assess the
16

level of similarity between the HRR+ group and the BRCA group. This analysis revealed a highly
significant similarity between these groups as well as between the PALB2 mutated samples
considered alone (Table 4). However, these relationships were not significant in the gene
expression data (Table 4).

Table 4 - P-values of analyses of PALB2 and HRR+ patients.
BRCA1
Gene
expression

BRCA2
Gene
expression

BRCA1&2
Gene
expression

BRCA1
Mutational
signatures

BRCA2
Mutational
signatures

BRCA1&2
Mutational
signatures

PALB2

0.215

0.231

0.199

<0.001

<0.001

<0.001

HRR+

0.949

0.850

0.923

<0.001

<0.001

<0.001
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DISCUSSION
Our analysis comparing mutational signature profiles of BRCA patients to BRCAness
patients revealed statistically significant similarity between the two groups. Additionally, our
analysis comparing BRCA patients to Other patients revealed significant difference between the
two groups. The results of this analysis suggest that BRCA patients are more similar to
BRCAness patients than they are to Other patients in terms of mutational signature profiles, and
also that mutational signature profiles could be an indicator of BRCAness. The results also
suggest that in terms of mutational signature data, our method of categorizing BRCAness
patients using BRCA1/2 hypermethylation, somatic mutations, and homozygous chromosomal
deletions is a valid method for categorizing BRCAness patients. Our results also suggest that
additional patients who cluster with the signature 3 patients—especially those who carry
germline mutations in PALB2, BARD1, RAD51B, or RAD51C—could be classified into the
BRCAness category. Future steps could include analyzing if a patient without a germline
BRCA1/2 mutation who has a high weight in Signature 3 should be categorized as BRCAness,
despite not having the other biomarkers we used to categorize BRCAness.
The analysis between BRCA and BRCAness patients in the gene-expression data did not
reveal statistically significant similarity overall, suggesting that BRCAness patients do not
necessarily have similar gene expression profiles as BRCA patients under our categorization
methods and that the downstream effects of HRR inactivation are less well reflected in geneexpression profiles than they are in mutational signatures. However, comparisons between
BRCA and BRCAness patients did reveal similarities between some sub categories of patients
for the gene expression data. In particular, there is significant similarity between BRCA patients
and patients with hypermethylation in BRCA1 and BRCA2.
18

When using the mutational-signature data to compare individuals with BRCA1 germline
mutations against individuals with BRCA2 mutations, we observed that mutations in these genes
have a similar effect on a patient's mutational signature profile. However, there was a significant
difference between the gene-expression profiles of patients in these groups. Since the difference
between the two groups is significant, it also suggests that germline BRCA1/2 mutations affect a
patient’s gene expression profile, but that the effects of each of these genes is different from each
other. For medical treatments based off of a patient’s gene expression profile, patients with
germline BRCA1/2 mutations should perhaps be considered separately from each other.
In regards to comparisons of patients with germline BRCA1/2 mutations, there is
significant similarity in both gene expression profiles and in mutational signature profiles to
patients with somatic BRCA1/2 hypermethylation. Also, in the case of the mutational signature
profiles, there is also significant similarity between patients with germline BRCA1/2 mutations,
and patients with somatic BRCA1/2 large scale deletions, as well as significant similarity
between patients with germline BRCA2 mutations, and patients with somatic BRCA2 mutations.
In regards to “BRCAness’, this suggests that somatic hypermethylation in BRCA1/2 is an
indicator for BRCAness in breast cancer patients in both mutational signature profiles, and gene
expression profiles. This also suggests that large scale BRCA1/2 deletions and somatic mutations
could be indicators of BRCAness in regards to mutational signature profiles.
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APPENDIX: SUPPLEMENTARY MATERIALS

Figure A.1 - Bar chart showing the proportion of patients in each subtype, colored by what
BRCA category they fall in.
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Figure A.2 - Example of one patient’s mutational signature.

Figure A.3 - Scatterplot showing selected germline mutations in samples in the mutational
signature data.
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Figure A.4 - Scatterplot showing selected germline mutations in samples in the gene expression
data.
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